Advances in omalizumab treatment for IgE-mediated food allergies
10.12025/j.issn.1008-6358.2025.20241062
- VernacularTitle:奥马珠单抗在IgE介导食物过敏治疗中的应用进展
- Author:
Siqi WANG
1
;
Ling YE
1
;
Meiling JIN
1
Author Information
1. Department of Allergy, Zhongshan Hospital, Fudan University, Shanghai 200032, China;Research Center of Allergy and Diseases, Fudan University, Shanghai 200032, China.
- Publication Type:Review
- Keywords:
food allergy;
immunoglobulin E;
omalizumab;
oral immunotherapy
- From:
Chinese Journal of Clinical Medicine
2025;32(4):675-684
- CountryChina
- Language:Chinese
-
Abstract:
The increasing prevalence of food allergies significantly affects both the physical and mental health of patients, while concurrently imposing a substantial economic burden on a global scale. Immunoglobulin E (IgE)-mediated food allergies typically manifest as acute reactions and may lead to severe allergic responses. Previous treatment strategies have been predominantly centered on allergen avoidance and oral immunotherapy (OIT), resulting in augmented economic and psychological burdens. In recent years, omalizumab, the anti-IgE monoclonal antibody, has emerged as a treatment option, either as monotherapy or in combination with OIT, for patients with IgE-mediated food allergies. Omalizumab holds promise in augmenting allergen tolerance, accelerating desensitization processes, and mitigating adverse effects associated with OIT. Nonetheless, a multitude of unresolved inquiries persist concerning the practical applications of omalizumab, necessitating additional real world studies for clarification.
